Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 16/20 | 0.43 |
| ▸ | PPARA | Q07869 | 15/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407017 | 0.86 | KDM4E (0.47) | KDM4EFFAR1PPARGPPARAKDR | |
| SCHEMBL4037802 | 0.85 | KDM4E (0.50) | KDM4EFFAR1PPARGPPARAKDR | |
| SCHEMBL5407125 | 0.85 | PPARG (0.49) | KDM4EFFAR1PPARGPPARA | |
| SCHEMBL6998371 | 0.84 | KDM4E (0.53) | KDM4EFFAR1PPARGPPARAKDR | |
| SCHEMBL5395193 | 0.83 | FFAR1 (0.61) | KDM4EFFAR1PPARGPPARAKDR | |
| SCHEMBL5393169 | 0.81 | FFAR1 (0.47) | KDM4EFFAR1PPARGPPARAKDR | |
| SCHEMBL4031813 | 0.79 | KDR (0.64) | KDM4EFFAR1PPARGPPARAKDR | |
| SCHEMBL5395507 | 0.79 | PPARG (0.63) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL5411057 | 0.78 | CYSLTR1 (0.41) | FFAR1 | |
| SCHEMBL5403520 | 0.78 | PPARG (0.48) | FFAR1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241785-B2 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-10 | — | — | US | disclosed |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1394154-A1 | FIVE-MEMBERED HETEROCYCLIC ALKANOIC ACID DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | SLC5A1, AHR, ALOX5 | KDM4E 1421/4885FFAR1 14/4885PPARG 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.